+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Adrenal disorders affect the glands above the kidneys that produce hormones involved in stress responses, blood pressure, and salt balance. They include adrenal insufficiency, Cushing syndrome caused by excess cortisol, and primary aldosteronism caus...

Search Bar & Filters

Found 31 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome who are treated with osilodrostat combined with glucocorticoid replacement therapy. The study also aims to assess new steroid biomarkers for dosing adequacy, and to monitor the safety, durability, and clinical improvement during treatment. The treatment starts with a Phase 1 titration period where participants take osilodrostat with added methylprednisolone as replacement therapy. Osilodrostat dosage is gradually increased to reach targeted cortisol levels, while participants are closely monitored. After reaching maintenance doses, participants enter Phase 2, a maintenance phase lasting 48 weeks, during which cortisol levels and other clinical measures are periodically assessed. Participants provide informed consent and receive frequent assessments including blood and urine tests for cortisol and steroid profiles. Communication with study staff is frequent in the early treatment phase to monitor for adrenal insufficiency signs. Outcome measures include adrenal insufficiency events, cortisol levels, symptom frequency, blood pressure, weight changes, medication use, and quality of life scores. The study lasts approximately 48 weeks from the first osilodrostat dose.

Age: 18Years - 75YearsAll Genders
1 location
E

Actively Recruiting

Neuroendocrine neoplasms NENs are rare cancers found in various body parts like the gastrointestinal tract, pancreas, lungs, and adrenal glands. These cancers often have a high risk of returning and low survival rates, highlighting the need for better treatments. This trial evaluates a new drug called ADCT-701 in adults with NENs, adrenocortical carcinoma, or malignant peripheral nerve sheath tumors to find the maximum tolerated dose. Participants receive ADCT-701 through an intravenous infusion on the first day of a 21-day treatment cycle. Dosing will be adjusted based on tolerance in a dose-finding design with up to ten dose levels. Clinic visits occur frequently during the first two cycles, then less often in subsequent cycles, with treatment lasting up to two years. The study includes physical exams, blood and urine tests, imaging scans, heart function tests, and possibly tumor biopsies. Participants will be followed after treatment ends with regular clinic visits over several years. These visits include physical exams, heart and blood tests, and imaging scans to monitor health and the drugs effects. The study aims to measure the drugs safety, maximum tolerated dose, anti-tumor activity, pharmacokinetics, and immune response over time, with total participation lasting up to five years from treatment start.

Age: 18Years - 120YearsAll GendersPhase 1
1 location
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and early signs of effectiveness of DS9051b in adults with advanced or metastatic adrenocortical carcinoma ACC and metastatic castration-resistant prostate cancer mCRPC. This first-in-human phase 1 trial aims to find the highest dose that can be given safely and to understand how the drug behaves in these patients. The study is sponsored by Daiichi Sankyo and focuses on these two serious cancer types. Participants will receive DS9051b orally as part of a dose escalation process to determine the maximum tolerated dose and the best dose for further study. The trial is open-label and involves multiple centers. All participants receive the experimental drug, and there are no placebo or comparator groups. The treatment period can last up to 50 months, during which various doses will be tested and adjusted based on safety and tolerability. Throughout the study, participants will be closely monitored for side effects, including dose-limiting toxicities and serious adverse events. Researchers will assess treatment responses using imaging and clinical evaluations, documenting disease control and progression. Visits include laboratory tests, physical exams, and assessments of cancer status. The study will also measure progression-free survival and duration of response over the course of up to 50 months, with ongoing safety follow-up during this period.

Age: 18Years +All GendersPhase 1
6 locations
S

Actively Recruiting

Glucocorticoids are hormones that help control inflammation and regulate the immune system. In children with blood cancers like acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, these hormones are given as medications to quickly reduce cancer cells. However, this treatment can suppress the bodys natural glucocorticoid production, leading to a deficiency that increases infection risks and is hard to detect due to overlapping chemotherapy side effects. This study aims to understand how often and for how long this deficiency occurs in children with these cancers and to identify those at higher risk. The study observes children diagnosed with ALL or LBL who are treated with glucocorticoids for at least 21 consecutive days. Regular low-dose ACTH tests will be performed during and after treatment to assess the bodys natural glucocorticoid production. These tests are done only when children already have venous access and are hospitalized for treatment, minimizing extra burden. The study follows participants from enrollment until three months after their last glucocorticoid dose. Participants will be monitored through these ACTH tests to detect adrenal insufficiency and its duration. The main outcome measured is the occurrence of adrenal insufficiency, with a secondary focus on how long it lasts. The study involves children up to 18 years old and takes place at two childrens hospitals. The goal is to improve understanding and management of glucocorticoid deficiency during and after cancer treatment, with careful attention to the safety and comfort of the children involved.

Age: 0 - 18YearsAll Genders
2 locations
S

Actively Recruiting

Researchers are investigating the causes and development of adrenal tumors, which include adrenocortical carcinoma, Cushing syndrome, Conn syndrome, and pheochromocytoma. The study aims to better understand how these tumors form and to evaluate new treatment options for patients with malignant adrenal tumors, addressing the limited current therapies available. This observational research is sponsored by the University of Wuerzburg and has been ongoing since 2002. Participants in the study may provide tumor material and related biological samples if they have adrenal tumors. Additionally, biological samples are collected from patients without adrenal tumors to serve as comparison controls. The research does not involve experimental treatments but focuses on collecting and analyzing biospecimens to explore tumor biology and potential therapies. Throughout the study, participants contribute by providing tumor and biosample materials. Researchers analyze these samples to study tumor characteristics and evaluate possible new treatments. There are no specific outcome measures listed. The study is observational, with no assigned treatments, and aims to gather information to support future therapeutic developments. Participants involvement duration varies, and the study is expected to continue until December 2032.

Age: 0 - 100YearsAll Genders
1 location
C

Actively Recruiting

Healthy Volunteer

Researchers are studying primary aldosteronism PA, a condition where the adrenal gland produces too much aldosterone, leading to high blood pressure and low potassium. The study focuses on Black individuals, including African Americans and those of Caribbean descent, to identify genetic causes of PA and understand the effects of these mutations on adrenal tumors and aldosterone production. The research also explores potential medicines to treat PA by blocking inappropriate aldosterone production. Participants include Black adults aged 18 to 70 with difficult-to-control blood pressure or diagnosed PA, as well as relatives aged 7 and older of people with PA. Those with PA or suspected PA undergo initial screening visits lasting 1 to 2 hours and, if eligible, a hospital stay for 7 to 10 days involving various tests such as blood and urine tests, scans, heart and kidney evaluations, and bone density scans. Relatives have a single visit for medical history and blood tests. Treatments, including adrenal gland removal surgery or aldosterone-blocking drugs, may be offered based on test results. During the study, participants undergo evaluations including medical history, physical exams, blood and urine tests, imaging scans, and sample collections such as a small hair sample. Follow-up visits occur 2 to 4 weeks after surgery if performed, and participants may return about one year later for repeat testing. Researchers measure genetic mutations, tumor function, aldosterone levels, and health effects on heart, kidneys, metabolism, bones, and blood clotting. The study aims to improve understanding of PAs impact and identify effective treatments for Black patients.

Age: 7Years - 70YearsAll Genders
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying how circadian genes in blood cells behave in people with hormonal disorders affecting glucocorticoid levels, including Cushings Syndrome during active disease, treatment, remission, and adrenal insufficiency with glucocorticoid replacement therapy. The study is prospective, multicenter, and intervention-based, aiming to explore disruptions in the bodys internal clock related to these conditions. Participants include patients with adrenal insufficiency, Cushings Syndrome, obesity, and those starting systemic glucocorticoid therapy for other conditions, along with healthy controls matched by age, sex, and BMI. All participants will undergo gene expression tests at baseline and follow-ups at 1, 3, and 6 months, with some groups having extended monitoring to 12 months. The study also involves assessments of immune cells, inflammatory markers, cortisol rhythms, sleep quality, infections, blood pressure, quality of life, psychological state, sexual function, insulin resistance, and lipid profiles. During the study, participants attend up to four visits where blood samples and other measurements are collected at specific times during the day to evaluate circadian patterns. They complete questionnaires on sleep, mood, quality of life, and sexual function. Advanced tests such as flow cytometry, steroid profiling, and continuous glucose monitoring may be performed. The primary focus is measuring circadian gene expression changes over time compared to healthy controls, alongside extensive monitoring of related health factors and biomarkers.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
1 location
D

Actively Recruiting

Researchers are evaluating the effectiveness of the immunotherapy drug dostarlimab as a first treatment option for adults with certain advanced or metastatic cancers that have a specific genetic feature called deficient mismatch repair dMMR or microsatellite instability MSI. This study focuses on cancers that are not colorectal or endometrial, including types such as duodenum, small bowel, gastric, pancreatic, ampulla of Vater, adrenocortical carcinoma, neuroendocrine carcinoma, carcinoma of unknown primary, and soft tissue sarcoma. The goal is to compare dostarlimab with the current standard chemotherapy treatments in a phase II clinical trial setting. After signing consent, patients undergo a pre-inclusion period of up to 28 days for eligibility assessments, including confirmation of dMMRMSI status through centralized testing. Participants are then randomly assigned to one of two groups one receives dostarlimab intravenously at 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks thereafter the other group receives standard chemotherapy according to current care guidelines. Treatment continues until disease progression, unacceptable side effects, death, or for a maximum of 24 months. Patients initially on chemotherapy who experience disease progression may switch to receive dostarlimab following a washout period. Participants undergo tumor evaluations at the start and regularly during treatmentevery 6 weeks during the first year and every 12 weeks in the second year. After treatment ends, follow-up visits occur every 16 weeks for up to a year. Throughout the study, researchers monitor progression-free survival, response rates, overall survival, circulating tumor DNA levels, side effects, and quality of life using questionnaires. The entire participation may last up to 3 years, including treatment, crossover, and follow-up phases.

Age: 18Years +All GendersPhase 2
22 locations
S

Actively Recruiting

Researchers are evaluating the effect of supplemental hydrocortisone compared with placebo during mild to moderate physical or mental stress on health-related quality of life in patients with polymyalgia rheumatica PMR or giant cell arteritis GCA who are on ongoing low-dose prednisolone and have glucocorticoid-induced adrenal insufficiency. The main focus is on reducing fatigue and understanding the daily variation of fatigue during stress. This is a phase 4, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Participants with PMR or GCA on low-dose prednisolone greater than 0 mgday and up to 5 mgday will have a Synacthen test to assess adrenal function. Those with adrenal insufficiency cortisol response below 420 nmoll will be randomized to receive either supplemental hydrocortisone or placebo during stress, while continuing prednisolone treatment and tapering according to clinical guidelines. Severe stress situations requiring urgent care will be treated openly with hydrocortisone. The study duration is 6 months, but may end earlier if prednisolone treatment stops sooner or be extended if prednisolone dosage increases due to disease flare. During the study, participants will undergo screening, baseline assessments, and report health-related quality of life for 3 months using ecological momentary assessments and patient-reported outcomes via an app. Follow-up includes medical record review on prednisolone treatment and hospitalizations. Multiple secondary assessments include body composition, muscle strength tests, bone quality scans, metabolic and cardiovascular risk markers, and integrated cortisol status measured at baseline, 3 months, and 6 months. The primary outcome is fatigue measured multiple times daily in stress situations.

Age: 50Years +All GendersPhase 4
3 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying salivary cortisol levels to develop normal reference ranges and identify optimal cut-off points for diagnosing Cushings syndrome and adrenal insufficiency. This observational study aims to help improve the use of saliva tests, which provide a non-invasive way to measure cortisol, a hormone important for assessing endocrine health. The study uses advanced methods to measure very low cortisol levels accurately, addressing challenges in current testing techniques. Participants include three groups healthy volunteers, patients diagnosed with Cushings syndrome, and patients with adrenal insufficiency. The study will collect saliva samples at specific times 800, 1600, and 2300 to establish reference intervals in healthy individuals and determine diagnostic cut-offs in patients. Two new testing technologies will be evaluated for clinical use, including a simplified immunomagnetic-bead-based assay and a fluorescence immunoassay suitable for point-of-care testing. During the study, participants will provide saliva samples at specified times on the day of collection. Researchers will analyze the samples to measure cortisol levels and compare results among groups by age, sex, and body mass index. The primary outcomes include establishing normal cortisol ranges and diagnostic accuracy for the conditions studied. The study will continue until the end of 2027, with careful monitoring of results to support clinical adoption of these new saliva testing methods.

Age: 18Years - 80YearsAll Genders
1 location

1-10 of 31

1